Viking Therapeutics is trading at $31.70, down 4.04%; its September 29 decline followed the closing of its upsized stock and convertible-note offerings. - The offerings raised approximately $575 million gross. - The stock offering included 9,035,714 shares priced at $35.00; financing-related dilution is a reported concern as shares continue to retreat. - Available sources do not establish a separate September 29 announcement as the cause. Provided broad indexes were mixed, offering less direct explanation for the move.